Join
Live feed
·
PRReleasevia Quantisnow
Unicycive Therapeutics Inc. logo

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

ByQuantisnow·Wall Street's wire, on your screen.
UNCY· Unicycive Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track UNCY (Unicycive Therapeutics Inc.) and more on Quantisnow.